Tokyo - Delayed Quote JPY

Hisamitsu Pharmaceutical Co., Inc. (4530.T)

Compare
4,642.00
+2.00
+(0.04%)
At close: 3:30:00 PM GMT+9
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
2/29/2024
2/28/2023
2/28/2022
2/28/2021
Total Revenue
150,185,000.00
141,706,000.00
128,330,000.00
120,193,000.00
114,510,000.00
Cost of Revenue
65,452,000.00
62,735,000.00
55,630,000.00
50,126,000.00
45,337,000.00
Gross Profit
84,732,000.00
78,970,000.00
72,699,000.00
70,067,000.00
69,173,000.00
Operating Expense
70,955,000.00
65,803,000.00
61,099,000.00
60,730,000.00
58,501,000.00
Operating Income
13,777,000.00
13,167,000.00
11,600,000.00
9,337,000.00
10,672,000.00
Net Non Operating Interest Income Expense
2,870,000.00
2,546,000.00
879,000.00
133,000.00
553,000.00
Pretax Income
20,649,000.00
19,186,000.00
16,113,000.00
12,956,000.00
12,197,000.00
Tax Provision
5,487,000.00
4,754,000.00
3,987,000.00
3,093,000.00
2,764,000.00
Net Income Common Stockholders
14,650,000.00
13,969,000.00
11,742,000.00
9,658,000.00
9,250,000.00
Diluted NI Available to Com Stockholders
14,650,000.00
13,969,000.00
11,742,000.00
9,658,000.00
9,250,000.00
Basic EPS
195.99
181.62
148.01
118.92
113.22
Diluted EPS
195.74
181.42
147.88
118.84
113.11
Basic Average Shares
75,141.05
76,918.55
79,340.06
81,213.00
81,707.00
Diluted Average Shares
75,232.89
76,998.13
79,402.22
81,268.93
81,778.80
Total Operating Income as Reported
13,777,000.00
13,167,000.00
11,599,000.00
9,337,000.00
10,671,000.00
Total Expenses
136,407,000.00
128,538,000.00
116,729,000.00
110,856,000.00
103,838,000.00
Net Income from Continuing & Discontinued Operation
14,650,000.00
13,969,000.00
11,742,000.00
9,658,000.00
9,250,000.00
Normalized Income
13,290,860.96
14,353,272.00
11,705,103.00
9,415,241.00
9,154,148.00
Interest Income
2,897,000.00
2,564,000.00
894,000.00
153,000.00
563,000.00
Interest Expense
27,000.00
18,000.00
15,000.00
20,000.00
10,000.00
Net Interest Income
2,870,000.00
2,546,000.00
879,000.00
133,000.00
553,000.00
EBIT
20,676,000.00
19,204,000.00
16,128,000.00
12,976,000.00
12,207,000.00
EBITDA
26,364,000.00
24,376,000.00
21,080,000.00
17,297,000.00
16,286,000.00
Reconciled Cost of Revenue
65,452,000.00
62,735,000.00
55,630,000.00
50,126,000.00
45,337,000.00
Reconciled Depreciation
5,688,000.00
5,172,000.00
4,952,000.00
4,321,000.00
4,079,000.00
Net Income from Continuing Operation Net Minority Interest
14,650,000.00
13,969,000.00
11,742,000.00
9,658,000.00
9,250,000.00
Total Unusual Items Excluding Goodwill
1,851,000.00
-511,000.00
49,000.00
319,000.00
124,000.00
Total Unusual Items
1,851,000.00
-511,000.00
49,000.00
319,000.00
124,000.00
Normalized EBITDA
24,513,000.00
24,887,000.00
21,031,000.00
16,978,000.00
16,162,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
491,860.96
-126,728.00
12,103.00
76,241.00
28,148.00
2/28/2021 - 1/1/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4887.T Sawai Group Holdings Co., Ltd.
2,027.00
+0.67%
 
4540.T Tsumura & Co.
4,528.00
+0.33%
 
4521.T Kaken Pharmaceutical Co., Ltd.
4,292.00
+1.35%
 
600085.SS TONGRENTANG
36.75
+0.14%
 
600079.SS HUMANWELL HEALTHCARE
21.89
-0.27%
 
000999.SZ China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
44.18
+0.61%
 
000963.SZ Huadong Medicine Co., Ltd
34.11
-0.93%
 
002001.SZ Zhejiang NHU Company Ltd.
22.49
+0.40%
 
ALKEM.BO Alkem Laboratories Limited
5,026.80
-2.95%
 
600196.SS FOSUN PHARM
23.81
+0.63%